Latest Information

  • Prometic presents new PBI-4050 and Ryplazim (plasminogen) data on long fibrosis at the 2019 ATS conference

    Prometic presents new PBI-4050 and Ryplazim (plasminogen) data on long fibrosis at the 2019 ATS conference

    Prometic today announced the presentation of three scientific posters on the Company’s lead small molecule and plasma-derived drug product candidates, respectively PBI-4050 and Ryplazim™.

    Read Article
  • Prometic announces terms of equity rights offering

    Prometic announces terms of equity rights offering

    Prometic is pleased to confirm the terms of its previously announced equity rights offering for gross proceeds of up to $75,000,000.

    Read Article
  • Prometic reports its 2019 first quarter financial results

    Prometic reports its 2019 first quarter financial results

    We made excellent progress during the quarter towards completing the necessary development work to permit re-filing of our Ryplazim™ (plasminogen) (“RyplazimTM ”) BLA before the end of 2019

    Read Article
  • Prometic strengthens its leadership with a new management structure and the appointment of three new directors

    Prometic strengthens its leadership with a new management structure and the appointment of three new directors

    Prometic is pleased to announce today a new management structure to provide leadership to the Corporation and the appointment of Dr. Gary Bridger, Mr. Timothy Wach and Mr. Neil Klompas to the Board.

    Read Article
  • Press Releases

    Read More
  • Annual Report 2018

    Annual Report 2018

    2018 was once again a year filled with strong scientific and clinical program development achievements for Prometic.

    Read PDF
  • Quarterly Report 2018 Q3

    Quarterly Report 2018 Q3

    Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manufacturing process along with Substantial reduction in R&D costs of up to $30 million.

    Read PDF
  • Quarterly Report Q2 2018

    Quarterly Report Q2 2018

    Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).

    Read PDF
  • Financial Reports

    Read Now
  • Corporate Governance and Nominating Committee Charter 2017

    Corporate Governance and Nominating Committee Charter 2017

    The Board of Directors of Prometic Life Sciences Inc. is ultimately responsible for the stewardship of the Corporation which means that it oversees the direction of the Corporation.

    Read PDF
  • Board of Directors Charter 2017

    Board of Directors Charter 2017

    Read PDF
  • Audit, Risk and Finance Committee Charter 2017

    Audit, Risk and Finance Committee Charter 2017

    The Committee is mainly responsible for the corporation's financial reporting process, process to identify & manage risks, internal & external audit process, communication systems & capital structure.

    Read PDF
  • Chairman Mandate 2018

    Chairman Mandate 2018

    The chairman of the Board of Directors of Prometic Life Sciences Inc. chairs the meetings of the Board and assures its good functioning and the good functioning of the committees of the Board.

    Read PDF
  • Code of Ethics and Business Conduct 2017

    Code of Ethics and Business Conduct 2017

    Full detailed breakdown of Prometics Code of Ethics and Business Conduct for 2017 including details on regulatory compliance.

    Read PDF
  • Corporate Governance

    Read More
  • Virtual Tour of Prometic Life Science's Manufacturing Process6:14

    Virtual Tour of Prometic Life Science's Manufacturing Process

    You will discover how our industry leading technology is now being used to extract and purify therapeutic proteins from human plasma to provide for the development of best in class products.

    Watch Video
  • PLI Share Price

    View Now
  • Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency2:17

    Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency

    At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).

    Watch Video
  • ×

    Subscribe to our mailing list and be the first to know

    First Name
    Last Name
    * By completing and submitting this form, you understand and agree that use of Prometic’s web site is subject to Prometic’s Privacy Policy
    !
    Thank you!
    Error - something went wrong!
  • Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment1:41

    Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment

    Prometic Life Science's senior director details the promising efficacy PBI-4050 alone or in combination with nintedanib demonstrated for treatment of IPF.

    Watch Video
  • Interested in Investment Opportunities?

    Contact Us
  • loading
    Loading More...